Novo Nordisk A/S
NVOHealthcare Drug Manufacturers General
Novo Nordisk A/S’s revenue for fiscal 2025 (year ended December 2025) was $46.8 billion, up 11.1% from fiscal 2024.
- Revenue
- +3.87%
- EPS
- −17.1%
- Free cash flow
- −14.8%
- Total debt
- +30.7%
Quarter to September 2026, against a year earlier
Follow NVO
Alert me
Novo Nordisk A/S (NVO) P/E ratio
As of Nov 19, 2026, Novo Nordisk A/S (NVO) trades at a P/E ratio of 9.8×. Over the past ten years it has ranged from 8.6× (April 2026) to 50.7× (June 2024); the current reading is higher than 2% of that period. That is below the Drug Manufacturers General industry median of 25.3× and below the Healthcare sector median of 22.4×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 14.7× | (43.92%) |
| FY2024 | 26.1× | (30.74%) |
| FY2023 | 37.7× | (4.36%) |
| FY2022 | 39.5× | 16.65% |
| FY2021 | 33.8× | 33.20% |
| FY2020 | 25.4× | 7.97% |
| FY2019 | 23.5× | 29.18% |
| FY2018 | 18.2× | (21.64%) |
| FY2017 | 23.2× | 44.31% |
| FY2016 | 16.1× | (44.26%) |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 9.5× | (18.53%) |
| Jun 2026 | 11.7× | 35.87% |
| Mar 2026 | 8.6× | (41.17%) |
| Dec 2025 | 14.7× | (9.10%) |
| 43 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| GILD Gilead Sciences, Inc. compare | n/m |
| NVO Novo Nordisk A/S | 9.8× |
| BMY Bristol Myers Squibb Company compare | 12.9× |
| GSK GSK PLC Sponsored ADR compare | 16.4× |
| SNY Sanofi compare | 22.8× |
| AZN AstraZeneca PLC compare | 24.6× |
| AMGN Amgen Inc. compare | 25.2× |
| NVS Novartis AG compare | 28.8× |
| PFE Pfizer Inc. compare | 38.8× |
| Drug Manufacturers General industry median | 25.3× |
| Healthcare sector median | 22.4× |
| Market median | 16.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on NVO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement